Glaukos Corp (GKOS)

Glaukos Corp.'s stock price has increased significantly by 63.24% over the past six months. Strong financial results, including record net sales for Q3 2025, Q4 2025, and Q1 2026, and raised 2026 net sales guidance have positively impacted the stock. FDA approval and commercialization of iDose TR and Epioxa have also been significant catalysts. Analyst sentiment is optimistic, with a "Moderate Buy" to "Strong Buy" rating. As of May 1, 2026, the stock price was $140.22, up from $112.80 on January 1, 2026, and is near its 52-week high of $146.75.

Demand for Glaukos Corp.'s products and services exhibits seasonality. Demand for U.S. ophthalmic procedures is typically softer in the first quarter and stronger in the fourth quarter. The company has experienced more pronounced seasonality headwinds in August for both its U.S. Glaucoma and U.S. Corneal Health businesses, which were offset by strength in July and September during the third quarter of 2023.

Glaukos Corporation is an ophthalmic medical technology and pharmaceutical company focused on developing and commercializing dropless therapies for glaucoma, corneal disorders, and retinal diseases. The company operates in the Health Care sector, specifically in the Health Care Equipment industry, and is known for pioneering Micro-Invasive Glaucoma Surgery (MIGS) with its iStent technology. Glaukos offers MIGS products like iStent, iStent inject W, and iStent infinite to reduce intraocular pressure. Procedural Pharmaceuticals, including iDose TR, deliver sustained medication release. Bio-activated Pharmaceuticals, such as Epioxa and Photrexa, address corneal disorders. Development-stage platforms include ILution for transdermal drug delivery and retinal XR for retinal diseases.

Glaukos Corporation's global headquarters is located in Aliso Viejo, California, United States. The company has additional facilities in the United States, Canada, the United Kingdom, Germany, Japan, Australia, and Brazil. Glaukos serves surgeons and patients across North America, Europe, Asia Pacific, and the Middle East through direct sales teams and strategic distribution partnerships.

Glaukos has a strong brand reputation due to its commitment to innovation and its pioneering role in the ophthalmic medical technology and pharmaceutical sector. The company focuses on transforming vision by developing novel, dropless platforms for chronic eye diseases and invests significantly in research and development, reinvesting approximately 35% of sales back into R&D. The release of its 2025 Sustainability Report reflects its commitment to corporate responsibility. There is no information indicating any specific negative events that have significantly affected Glaukos Corp.'s brand reputation in the past year.

Glaukos Corporation's ownership is predominantly institutional, with institutional investors holding approximately 58.74% to 99.04% of outstanding shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., and Primecap Management Co. Insider ownership, including executives like CEO Thomas W. Burns, is approximately 1.18% to 3.95% as of March 31, 2025. Public companies and individual investors hold the remaining shares, estimated around 23.49% to 37.31%.